Ampio enters into collaborative research agreements to explore additional clinical indications for Ampion

Ampio enters into collaborative research agreements to explore additional clinical indications for Ampion

ENGLEWOOD -- Ampio Pharmaceuticals, Inc . (NYSE American: AMPE) announced it has entered into two collaborative research agreements to explore new clinical indications for its immunomodulatory drug,... Read More

Monday December 14, 2020 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion, FDA, COVID-19

Ampio begins Phase 1 clinical trial of inhaled Ampion for COVID-19

Ampio begins Phase 1 clinical trial of inhaled Ampion for COVID-19

ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) announced it hasbegun recruiting and enrolling patients in a Phase Imulti-center, randomized, controlled trial for a total of 40... Read More

Thursday October 29, 2020 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion, COVID-19, Michael Macaluso

FDA grants IND and approves clinical trial protocol of inhaled Ampion for COVID-19 patients

FDA grants IND and approves clinical trial protocol of inhaled Ampion for COVID-19 patients

ENGLEWOOD-- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) announced it has received an Investigational New Drug designation from the U.S. Food and Drug Administration, allowing the company to... Read More

Monday September 21, 2020 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion, COVID-19, FDA

Ampio starts patient enrollment in its Ampion COVID-19 program

Ampio starts patient enrollment in its Ampion COVID-19 program

ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) today announced it is actively working on development of therapies for patients infected with COVID-19. Ampio said patients are... Read More

Thursday July 23, 2020 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion, COVID-19

Ampio to begin first clinical trial in COVID-19 program

Ampio to begin first clinical trial in COVID-19 program

ENGLEWOOD -- Ampio Pharmaceuticals, Inc . (NYSE American: AMPE) announced it is developing therapies for patients infected with the SARS-CoV-2 virus ("COVID-19"). The U.S. Food and Drug... Read More

Monday June 22, 2020 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion, COVID-19

Ampio provides update on COVID research program

Ampio provides update on COVID research program

ENGLEWOOD -- Ampio Pharmaceuticals, Inc . (NYSE American: AMPE),a biopharmaceutical company focused on the advancement of immunology-basedtherapies for prevalentinflammatory conditions, announced... Read More

Tuesday May 26, 2020 0 comments Tags: Englewood, Ampio Pharmaceuticals, COVID-19, Ampion

Ampio reports acceptance of publication on potential benefits of nebulized Ampion for COVID patients

Ampio reports acceptance of publication on potential benefits of nebulized Ampion for COVID patients

ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE),a biopharmaceutical company focused on the development of immunology-based therapies for prevalent inflammatory conditions,... Read More

Tuesday May 12, 2020 0 comments Tags: Englewood, Ampio Pharmaceuticals, COVID-19, Ampion

Ampio Pharmaceutical's FDA application for Ampion clinical study to treat COVID-19 ARDS on TV

Ampio Pharmaceutical's FDA application for Ampion clinical study to treat COVID-19 ARDS on TV

ENGLEWOOD -- Ampio Pharmaceuticals, Inc . (NYSE American: AMPE) announced it was featured on aFOXTV segment titled, "Englewoodpharmaceutical company looking to treat COVID-19 patients with... Read More

Friday April 3, 2020 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion, Michael Macaluso, FDA, COVID-19, ARDS